Abstract:Jing Li, 1, &ast Haitao Chen, 1, 2, &ast Jiaxuan Chen, 1, &ast Bin Zhou, 1 Jinlin Hou, 1 De-Ke Jiang 1 1 State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China; 2 School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, People's Republic of China &astThese authors contributed equally to this work Correspondence: De-Ke Jiang; Jinlin Hou State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China Tel +86-20-62786533 ; +86-20-61641941 Email ; Purpose: Granulysin (GNLY) is a cytotoxic granule that has been reported to have various antimicrobial activities. We evaluated the association between a missense variant in GNLY (rs11127) and treatment efficacy of pegylated interferon-alpha (PegIFNα) or nucleos(t)ide analogs (NUCs) in patients with chronic hepatitis B (CHB). Patients and Methods: We included a total of 1823 patients with hepatitis B e antigen (HBeAg)-positive CHB (954 patients treated with PegIFNα and 869 patients treated with NUCs) in four Phase IV multicenter randomized controlled trials. The association of the GNLY rs11127 genotype with the combined response (CR), defined as HBeAg seroconversion and hepatitis B virus (HBV) DNA level < 2000 IU/mL was evaluated. A polygenic score (PGS) was constructed to evaluate the cumulative effect of multiple single-nucleotide polymorphisms (SNPs), including rs11127 and several other SNPs, STAT4 rs7574865, CFB rs12614, and CD55 rs28371597, which were reported to be associated with CR. Results: GNLY rs11127 was significantly associated with CR in patients treated with PegIFNα. The CR rate in patients with the rs11127 CC genotype was higher than that with the CT or TT genotype (40.98% vs 30.34% or 27.09%, P = 0.003). Furthermore, a PGS integrating GNLY rs11127 and three other SNPs was significantly associated with CR in PegIFNα-treated patients ( P < 0.001). However, no significant correlation was found between GNLY rs11127 and CR in NUCs-treated patients. Conclusion: GNLY rs11127 is an independent biomarker for predicting the response to PegIFNα therapy in HBeAg-positive CHB patients. Furthermore, the PGS, including GNLY rs11127, provides new insights for individualized treatment in clinical practice. Keywords: GNLY , rs11127, chronic hepatitis B, PegIFNα treatment, polygenic score Chronic hepatitis B virus (HBV) infection remains a major concern for global health, with an estimated 292 million cases and approximately 30% in China. 1 Because of its high prevalence and severe health consequences, such as cirrhosis and hepatocellular carcinoma (HCC), chronic HBV infection imposes a substantial burden on patients and society. 2 The current first-line antiviral treatments can be classified into two categories: pegylated interferon-alpha (PegIFNα) and nucleos(t)ide analogs (NUCs). 3 NUCs have excellent performance in tolerability, high rates of biochemical remission, and effective inhibition of HBV replication; however, long-term therapies also incur increasing cost, safety profiles and compliance issues. As for PegIFNα treatment, despite its severe adverse reactions, it is also an alternative strategy with considerable efficacy in increasing hepatitis B s antigen (HBsAg) loss and reducing the incidence of cirrhosis and HCC. 4,5 According to the American Association for the Study of Liver Disease (AASLD) 2018 Hepatitis B Guidance, indicators such as HBV DNA suppression, HBeAg seroconversion or loss, normalization of alanine aminotransferase (ALT), and HBsAg loss, are provided to assess the efficacy of first-line antiviral therapies, including PegIFNα. 6 Combined response (CR), defined as HBeAg seroconversion along with HBV DNA level <2000 IU/mL, was also used to evaluate for IFN efficacy. 7,8 Regardless of NUCs or PegIFNα, the therapeutic response rate is limited. Therefore, it is important to identify novel biomarkers to predict the therapeutic efficacy. Accumulating evidence has demonstrated that host genetics could affect the response to IFNα treatment. 9,10 Notably, IL28B p -Abstract Truncated-

Genetic Variation in FCER1A Predicts Peginterferon Alfa‐2a‐induced Hepatitis B Surface Antigen Clearance in East Asian Patients with Chronic Hepatitis B

Association of Single Nucleotide Polymorphisms in Interferon Signaling Pathway Genes and Interferon-Stimulated Genes with the Response to Interferon Therapy for Chronic Hepatitis C

ZNF350 gene polymorphisms promote the response to Peg-IFNα therapy through JAK-STAT signaling pathway in patients with chronic hepatitis B

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

A Missense Variant In Complement Factor B (Cfb) Is A Potential Predictor Of 24-Week Off-Treatment Response To Pegifn Alpha Therapy In Chinese Hbeag-Positive Chronic Hepatitis B Patients

Evaluation of Susceptibility Locus for Response to Interferon-Α Based Therapy in Chronic Hepatitis B Patients in Chinese

Genetic Variation in STAT4 Predicts Response to Interferon‐α Therapy for Hepatitis B E Antigen‐positive Chronic Hepatitis B

Association between polymorphisms and interferon/ribavirin treatment response in hepatitis C virus type 1 infection in Chinese population: a prospective study.

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study

CXCL13 variant predicts pegylated‐interferon α treatment response in HBeAg‐positive chronic hepatitis B patients

The Association of LMP7 and TAP2 Gene Polymorphisms with Treatment Response to Interferon/ribavirin in Patients with Genotype 1 Chronic Hepatitis C.

No Association Between IFNL3 (IL28B) Genotype and Response to Peginterferon Alfa-2A in HBeAg-positive or -Negative Chronic Hepatitis B.

Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.

IFIT1 Polymorphisms Predict Interferon-Α Treatment Efficiency for Hepatitis B Virus Infection.

CXCR7 genetic variant predicts treatment response of pegylated-interferon α in HBeAg-positive chronic hepatitis B patients

An intronic genetic variant of ZHX2 predicts response to pegylated interferon α therapy in HBeAg-positive chronic hepatitis B patients

T29C Genotype Polymorphism of Estrogen Receptor Alpha is Associated with Initial Response to Interferon-Alpha Therapy in Chronic Hepatitis B Patients.

IMPACT OF IFNL-3 (IL-28B) POLYMORPHISM ON THE KINETICS OF HBV DNA AND QHBSAG AND HBSAG CLEARANCE DURING THERAPY WITH PEGINTERFERON α-2A IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B, GENOTYPE D

A Novel Polymorphism Near HLA Class II Region is Associated with Spontaneous Clearance of HCV and Response to Interferon Treatment in Chinese Patients

What are the limits of efficacy for immunotherapy against hepatocellular carcinoma and its clinical availability

A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B